Artificial Intelligence in Clinical Research

AI and Advanced Analytics to Support Clinical Trial Transformation

February 9 - 10, 2022 ALL TIMES EST

Artificial intelligence (AI) and machine learning (ML) have propelled many industries toward a new, highly functional and powerful state. Now they are starting to make their way into the clinical research realm advancing clinical operations, as well as data management. Many pharmaceutical companies and larger CROs are starting projects involving some elements of AI, ML, and robotic process automation in clinical trials. CHI’s 5th Annual Artificial Intelligence in Clinical Research conference is designed to facilitate the discussion and to accelerate the adoption of these approaches in clinical trials. Advisory Board: Faisal Khan, PhD, Executive Director, Advanced Analytics & AI, AstraZeneca Pharmaceuticals, Inc. Brian Martin, Head of AI, R&D Information Research, Research Fellow, AbbVie Prasanna Rao, Head, AI & Data Science, Data Monitoring and Management, Clinical Sciences and Operations, Global Product Development, Pfizer Inc.

Wednesday, February 9

ROOM LOCATION: Gatlin E1

BRIDGING LUNCHEON PRESENTATION

12:00 pm Bridging Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
12:30 pm Coffee and Dessert Break in the Exhibit Hall(Gatlin Ballroom BCD)

KEYNOTE LOCATION: Gatlin A1 & A2

DIVERSITY, EQUITY & INCLUSION (DE&I) AND SPEAKING THE LANGUAGE OF BUSINESS AND LEADERSHIP

1:30 pm KEYNOTE PRESENTATION:

Welcome Remarks from CHI and the SCOPE Team

Micah Lieberman, Executive Director, Cambridge Healthtech Institute (CHI)

Thank you all for being here from the SCOPE team: Micah Lieberman, Dr. Marina Filshtinsky, Kaitlin Kelleher, Bridget Kotelly, Mary Ann Brown, Ilana Quigley, Patty Rose, Julie Kostas, and Tricia Michalovicz

1:35 pm KEYNOTE PRESENTATION:

Why Advancing Inclusive Research is a Moral, Scientific, and Business Imperative

Meghan McKenzie, Principal, Inclusion, Patient Insights and Health Equity, Chief Diversity Office, Genentech

Our industry is rightfully focused on the importance of diversity, equity, and inclusion in clinical trials. Many of us have been focused on this in our work and/or in our advocacy, both inside and outside of our organizations for some time. Why is inclusivity so important to PIs and patients? Why is it both a moral and a business imperative? Learn why representation in clinical research matters for your patients and how it shapes good science. The face of the world is changing and your success is tied to reaching ethnic minorities.

2:00 pm KEYNOTE PRESENTATION:

Implicit Bias Around Advocacy and Decision Making: Metrics of DE&I and Speaking the Language of Business and Leadership

Panel Moderator:
Kimberly Richardson, Research Advocate, Founder, Black Cancer Collaborative

What is the perspective of Black professionals and patient advocates as the medical and scientific industries grapple with effective ways to engage minority population?  Where are their voices being heard and what can we learn from the cultural experiences they weave into their research methodologies and daily practices? Panelists will share their perspectives on how the Black voice should be included in advocacy and public and private aspects of clinical research. 

Panelists:
Karriem Watson, PhD, Chief Engagement Officer, NIH
Monique Phillips, Global Diversity and Inclusion Lead, Bristol Myers Squibb Co.
Nikhil Wagle, MD, Assistant Professor, Harvard Medical School, Dana-Farber Cancer Institute
2:45 pm Booth Crawl & Refreshment Break in the Exhibit Hall (Gatlin Ballroom BCD)

ROOM LOCATION: Gatlin E1

AI TO ENABLE CLINICAL INNOVATION

3:45 pm

Chairperson's Remarks 

Timothy Riely, Vice President, Clinical Data Analytics, IQVIA
3:50 pm

AI for Pfizer Vaccine Study 

Prasanna Rao, Head, AI & Data Science, Data Monitoring and Management, Clinical Sciences and Operations, Global Product Development, Pfizer Inc.

In this session, we will describe Pfizer's AI journey through the lens of clinical data, use cases, implementation and key to success. Clinical Data Management for the Vaccine Study presented an opportunity for ML/NLP to assist in saving valuable time reconciling data. The foundation for a Smart Data Quality strategy was expanded to other TAs thanks to the solution's Pattern Recognition, Clinical Inference capabilities that will be explained in detail.

4:20 pm

Driving Value from AI Insights

Timothy Riely, Vice President, Clinical Data Analytics, IQVIA

Once life sciences companies have proven the value and reliability of AI models, they need to deploy that insight to the right person at the right time to drive the right decision. This presentation will discuss how to implement AI in the workflow and discuss three examples where organizations have successfully done this.

Julie Smiley, Sr. Director Life Sciences Product Strategy, Oracle Health Sciences Global Business Unit, Oracle

Gaining insights from data has traditionally been a laborious and time-consuming effort. It includes ingestion of data from many sources, aggregation via programming, cleaning through listings review and validation checks, and provisioning of data to downstream stakeholders in various formats. This session explores the challenges with these processes and provides methods for automation with the use of artificial intelligence to accelerate access to downstream data consumers for quicker critical decision-making.

5:20 pm

AI in Drug Development: Opportunities and Pitfalls

Panel Moderator:
Prasanna Rao, Head, AI & Data Science, Data Monitoring and Management, Clinical Sciences and Operations, Global Product Development, Pfizer Inc.

AI/ML is over-hyped, this panel will discuss machine learning techniques that are in production in various organizations that are adding value and accelerating Clinical Development. We will also discuss best practices, lessons learnt, how to pick a ML use case from idea to implementation and more.

Panelists:
Brian Martin, Head of AI, R&D Information Research, Research Fellow, AbbVie, Inc.
Faisal Khan, PhD,
5:50 pm Close of Day

Thursday, February 10

7:15 am Registration Open and Breakfast (Gatlin Foyer)

ROOM LOCATION: Gatlin E1

8:55 am

Natural Language Understanding and Knowledge Graphs 

Malaikannan Sankarasubbu, Vice President, Artificial Intelligence Research, Saama Technologies, Inc.

Natural language understanding and knowledge graphs in pharma. Biomedical text mining is hard. Recent techniques, like transformers, trained on publically available data, like Pubmed, can give better language models for use in pharma. How do new techniques like transformers help with better language models? Knowledge graphs and graph convolutional network applications in pharma.

Jason Attanucci, Vice President and General Manager, Life Sciences, Deep 6 AI

Over 80% of healthcare information is buried in unstructured data like provider notes, pathology results and genomics reports. Leveraging AI and NLP technologies to mine, contextualize and temporalize medical concepts can have a dramatic effect on clinical trial operations. We discuss how effective use of this information can accelerate multiple operational objectives across the clinical trial continuum such as study design, site selection, patient recruitment, SAE adjudication, RWE and beyond.

9:40 am

AI for Clinical Data Utilization Across Full Product Cycle 

Brian Martin, Head of AI, R&D Information Research, Research Fellow, AbbVie, Inc.

This presentation will discuss approaches and case studies for extracting knowledge from clinical trial data and connecting it with preclinical and post-approval data.

Lucas Glass, Vice President, Analytics Center of Excellence, R&D Solutions, IQVIA

In feasibility, trial-sites are chosen based on medical expertise and patient access. Using principles of fairness in machine learning, a model that maps clinical trial descriptions to a ranked list of sites was developed and tested on real-world data. It resulted in a list of potential trial-sites that accounted for performance and diversity. This presentation looks at data sources and ML algorithms that could solve diversity problems in site selection.

10:40 am Networking Coffee Break (Gatlin Foyer)
Łukasz Kidziński, PhD, Director, AI, Clario
Kevin Thomas, PhD, Director, AI, Clario
Janine Jones, Senior Product Manager, Clario
David Billiter, Founder and CEO, Deep Lens

Artificial Intelligence has the potential to dramatically improve the speed and accuracy of clinical trials. Medical and operational experts can incorporate AI algorithms into use cases including automation of image analysis, predictive analytics about trends in the meta data, and tailored patient engagement for improved compliance. This panel will discuss opportunities for AI to help sponsor and site stakeholders focus more on patient outcomes and perform their jobs more effectively. 

 
12:00 pm Transition to Shared Sessions or Brief Session Break

AI FOR REAL WORLD AND TRIAL DESIGN APPLICATIONS

12:05 pm

Multimodal Clinical Prediction Models in Research and Beyond

Patrick Schwab, PhD, Director, Artificial Intelligence and Machine Learning, GSK

The widespread adoption of electronic health records (EHRs) alongside the advent of scalable clinical molecular profiling technologies has created enormous opportunities for deepening our understanding of health and disease. However, in most diseases, disease-relevant markers are spread across multiple biological contexts that are observed independently with different measurement technologies and at various time schedules, and their manual interpretation is therefore in many cases complex. Machine learning holds promise for integrating comprehensive, deep phenotypic patient profiles across time for (i) predicting outcomes, (ii) identifying patient subtypes and (iii) associated biomarkers. In this talk, we will outline opportunities and challenges for clinical prediction models built from deep phenotypic patient profiles in clinical research and beyond.

12:35 pm

Case Studies for AI-Based Intelligent Automation in Pharmacovigilance

Neal Grabowski, Director, Safety Data Science, AbbVie, Inc.

Learn which AI-based technologies are in production for which ICSR process steps. Understand various considerations for planning, implementation, and validation. Understand key learnings from early adopters of AI-based technologies within the ICSR process.

1:05 pm Transition to Lunch
SCOPE SEND-OFF LUNCHEON PRESENTATIONS

Come enjoy a luncheon with your peers while listening to your choice of two compelling industry presentations.

Nekzad Shroff, Vice President, Product Management, Saama Technologies
Aditya Gadiko, Director of Clinical Informatics, Saama Technologies

Today’s medical monitors are under tremendous pressure to quickly identify trends and signals that could impact patient safety and drug efficacy. This critical task is only getting more difficult as the volume of data–and the number of data sources–grows. This session will explore new approaches to medical monitoring, available now, that can simplify workflows and scale to meet the challenges posed by data volume, velocity, and variety.

Nicole Stansbury, Vice President, Clinical Monitoring, Central Monitoring Services, Syneos Health
1:45 pm SCOPE Summit 2022 Adjourns





SCOPE Summit Europe

2025 Conference Programs

Clinical Trial Venture, Innovation & Partnering *
*Separate Registration Required